Centessa Pharmaceuticals Files 8-K on Shareholder Votes

TL;DR

Centessa Pharma held a shareholder vote on 6/25/24. Details TBD.

AI Summary

Centessa Pharmaceuticals plc filed an 8-K on June 25, 2024, to report on matters submitted to a vote of its security holders. The filing does not contain specific details about the votes or resolutions presented.

Why It Matters

This filing indicates that Centessa Pharmaceuticals held a shareholder meeting where votes were cast on certain matters, which is a standard corporate governance event.

Risk Assessment

Risk Level: low — This is a routine corporate filing regarding shareholder votes, not indicating any immediate financial or operational risks.

Key Players & Entities

• Centessa Pharmaceuticals plc (company) — Registrant
• June 25, 2024 (date) — Date of Report

FAQ

Filing Documents

• cnta-20240625.htm (8-K) — 50KB
• 0001847903-24-000095.txt ( ) — 228KB
• cnta-20240625.xsd (EX-101.SCH) — 3KB
• cnta-20240625_def.xml (EX-101.DEF) — 16KB
• cnta-20240625_lab.xml (EX-101.LAB) — 30KB
• cnta-20240625_pre.xml (EX-101.PRE) — 18KB
• cnta-20240625_htm.xml (XML) — 4KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. On June 25, 2024, the Company held its 2024 Annual General Meeting (the "Annual General Meeting"). Proxies were solicited pursuant to the Company's definitive proxy statement filed on May 9, 2024 (the "Proxy Statement"), with the Securities and Exchange Commission under Section 14(a) of the Securities Exchange Act of 1934, as amended. The number of ordinary shares entitled to vote at the Annual General Meeting was 113,261,213. The number of shares of ordinary shares present or represented by valid proxy at the Annual General Meeting was 88,952,125, thus establishing a quorum for the Annual General Meeting. All matters submitted to a vote of the Company's shareholders at the Annual General Meeting were approved and the director nominees were elected. The voting results reported below are final. Ordinary Resolutions For Against Withheld Broker Non-Votes To re-appoint as a director, Francesco De Rubertis, Ph.D., who retires by rotation in accordance with the Company's articles of association. 67,765,652 8,942,960 12,521,500 — To re-appoint as a director, Saurabh Saha, M.D., Ph.D., who retires by rotation in accordance with the Company's articles of association 76,363,186 345,426 12,521,500 — To re-appoint as a director, Mary Lynne Hedley, Ph.D., who retires by rotation in accordance with the Company's articles of association. 76,585,872 137,983 12,506,257 — To re-appoint KPMG LLP, a United Kingdom entity, as U.K. statutory auditors of the Company, to hold office until the conclusion of the next meeting at which the Company's annual accounts and reports are laid before the Company. 88,878,408 73,717 277,987 — To ratify the re-appointment of KPMG LLP, a Delaware limited liability partnership, as the Company's independent registered public accounting firm, for the financial year ending December 31, 2024. 88,878,528 73,597 277,987 — To authorize the Audit Committee to determine the Company's auditors'

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 25, 2024 By: /s/ Saurabh Saha Name: Saurabh Saha, M.D., Ph.D. Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR